Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Market Videos
Currencies
International
Treasury & Bonds
Search InvestCenter
Recent Quotes
My Watchlist
Indicators
Cytokinetics, Inc. (NQ: CYTK)
1.160 USD  -0.020 (-1.69%)
Official Closing Price  /  Updated: 8:10 PM EDT, May 24, 2013  /  Add to My Watchlist      
View: Quote News Research
Press releases about Cytokinetics, Inc.
 
< Previous 1 2 3 4 5 6 7 8 9 Next >
Federal National Mortgage Association and Cytokinetics, Incorporated Trend Analysis Report: (OTCQB: FNMA), (NASDAQ: CYTK)
April 23, 2013
from SBWire Direct - Latest Press Releases
News and Commentary on High Volume Stocks: (NASDAQ: RVLT), (NASDAQ: CYTK)
April 22, 2013
from SBWire Direct - Latest Press Releases
Pre-Market Trading Commentary on High Volume Stocks: (NASDAQ: CYTK), (NASDAQ: ARRY)
April 15, 2013
from SBWire Direct - Latest Press Releases
Free Research Reports on CYTK, DELL, PIR and TM Issued by the Bedford Report
April 12, 2013
Note to Editors: The Following Is an Investment Opinion Being Issued by the Equity News Circuit Read More
from Marketwired News Releases
U.S. Food and Drug Administration Approved 30% More Drugs in 2012 Than the Year Previous
February 15, 2013
Research Driven Investing Provides Stocks Research on Cytokinetics and Pluristem Therapeutics Read More
from Marketwired News Releases
Biotech Industry Skyrockets in 2012 as FDA New Drug Approval Rate Increases
November 27, 2012
Five Star Equities Provides Stock Research on Cytokinetics and Galectin Therapeutics Read More
from Marketwired News Releases
Free Research Reports on ARO, CBAK, CYTK and OCLR Issued by the Bedford Report
November 27, 2012
The Following Is an Investment Opinion Being Issued by the Equity News Circuit Read More
from Marketwired News Releases
Cytokinetics Opens BENEFIT-ALS, A 400 Patient, Phase IIb Clinical Trial of Tirasemtiv in Patients with ALS
October 29, 2012
from PRWeb
New Legislation Passed to Help Speed Up FDA Review Process
September 17, 2012
The Paragon Report Provides Stock Research on Geron and Cytokinetics Read More
from Marketwired News Releases
M&A Activity in the Biotech Industry at a Four-Year High as Large Pharmaceuticals Look to Replace Lose Revenues
August 17, 2012
Five Star Equities Provides Stock Research on AEterna Zentaris and Cytokinetics Read More
from Marketwired News Releases
Cytokinetics, Incorporated Reports Second Quarter 2012 Financial Results
July 31, 2012
Company Updates Financial Guidance in Connection With Recent Financing and Announces Plans to Initiate Potential Registration Program for Tirasemtiv (CK-2017357) Read More
from Marketwired News Releases
Cytokinetics Announces Heart Failure Program Update
July 26, 2012
Oral Formulations of Omecamtiv Mecarbil Selected for Evaluation in Future Clinical Trials Read More
from Marketwired News Releases
Cytokinetics to Announce Second Quarter Results on July 31, 2012
July 24, 2012
from Marketwired News Releases
Cytokinetics to Present at 7th Annual JMP Securities Healthcare Conference
July 05, 2012
from Marketwired News Releases
Cytokinetics, Incorporated Announces $60 Million Financing
June 20, 2012
from Marketwired News Releases
Cytokinetics Announces Proposed Public Offerings of Common Stock and Warrants and Series B Convertible Preferred Stock and Warrants
June 19, 2012
from Marketwired News Releases
Cytokinetics, Incorporated Receives NASDAQ Notice of Minimum Bid Price Non-Compliance
June 19, 2012
from Marketwired News Releases
Cytokinetics Announces Publication of Phase II Evidence of Effect Study of CK-2017357 in the Journal Amyotrophic Lateral Sclerosis
June 12, 2012
from Marketwired News Releases
Cytokinetics Announces Opening of Second Cohort in Phase IIb Clinical Trial of Intravenous Omecamtiv Mecarbil in Patients With Acute Heart Failure
May 24, 2012
Independent Data Monitoring Committee Recommends Progression to Second Cohort Read More
from Marketwired News Releases
Cytokinetics to Hold Annual Meeting of Stockholders
May 15, 2012
from Marketwired News Releases
Cytokinetics Announces Company Participation and Support of ALS Fundraising Activities in Connection With ALS Awareness Month
May 09, 2012
from Marketwired News Releases
Cytokinetics, Incorporated Reports First Quarter 2012 Financial Results
April 26, 2012
Company Reviews Recent Advancements in Its Skeletal and Cardiac Muscle Contractility Programs Read More
from Marketwired News Releases
Cytokinetics Announces Presentation of Preclinical Data Regarding CK-2017357 at the 2012 Experimental Biology Annual Conference
April 26, 2012
Presentation Highlights Improvement in Resistance to Muscle Fatigue Read More
from Marketwired News Releases
Cytokinetics Announces Encouraging Results From Two Phase II Clinical Trials Evaluating CK-2017357 in Patients With Amyotrophic Lateral Sclerosis
April 25, 2012
Safety and Tolerability of CK-2017357 in These Two Trials Support Progression to Registration Stage Program Read More
from Marketwired News Releases
Cytokinetics to Announce First Quarter Results on April 26, 2012
April 19, 2012
from Marketwired News Releases
Cytokinetics Announces CK-2017357 Receives Fast Track Designation From the FDA for the Potential Treatment of Amyotrophic Lateral Sclerosis
April 19, 2012
from Marketwired News Releases
Cytokinetics Announces Clinical Trial Data Relating to CK-2017357 to Be Presented at the 64th Annual Meeting of the American Academy of Neurology
April 18, 2012
Additional Preclinical Trial Data to Be Presented at the 2012 Experimental Biology Conference Read More
from Marketwired News Releases
Cytokinetics to Present at the Eleventh Annual Needham Life Sciences Conference
March 27, 2012
from Marketwired News Releases
Cytokinetics Announces Changes to Its Board of Directors
March 07, 2012
Resignation of Jim Spudich and Election of Sandy Smith Read More
from Marketwired News Releases
Cytokinetics Announces That the European Medicines Agency Has Granted CK-2017357 Orphan Medicinal Product Designation for the Treatment of Amyotrophic Lateral Sclerosis
March 06, 2012
from Marketwired News Releases
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Telekurs USA
Postage Rates Bots go here